CMS Reviewing Aprepitant NCD To Add Use With Moderately Emetogenic Chemo
This article was originally published in The Pink Sheet Daily
Executive Summary
The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.